ADAPT SMART: a platform for coordinating Medicines Adaptive Pathways to Patients
ADAPT SMART is an enabling platform for the coordination of Medicines Adaptive Pathways to Patients (MAPPs) activities that aims to foster access to beneficial for patients with unmet needs, such as rare diseases at the earliest appropriate time in the product life-span in a sustainable fashion. ADAPT SMART is a 30-month project under IMI2 - the second phase of the Innovative Medicines Initiative (IMI) - which will work towards proving and developing workable MAPPs concepts.
IMI2 is a public-private partnership of the European Federation of Pharmaceutical Industries and Associations (EFPIA) and the European Commission. The IMI is working to improve health by speeding up the development of, and patient access to, innovative medicines, particularly in areas where there is an unmet medical or social need. It does this by facilitating collaboration between the key players involved in healthcare research.
Led by the European Medicines Agency (EMA), the this first of a kind coalition will engage relevant stakeholders, bringing together patients, regulators, industry, Health Technology Assessment (HTA) bodies, payers, and academics, to foster the development of MAPPs in Europe. The EMA believes that this will encourage more efficient ways of developing and regulating medicines thus providing patients with more appropriate access to innovative medicines.
Accordingly the ADAPT SMART consortium will do the following:
"Distribute findings, key discoveries and case studies from ongoing or completed MAPPs pilot projects, creating a MAPPs repository of knowledge and opportunities
Identify the scientific challenges and opportunities related to the implementation of MAPPs and foster the aligned understanding of consortium members and their constituents
Support new IMI2 research and innovation actions by facilitating the inclusion of MAPPs enablers, tools and methodologies to address its challenges and opportunities
Conduct horizon scanning and research on key topics to produce actionable advice and recommendations for IMI and other stakeholders to further the broad implementation and adoption of MAPPs"
It will centre its initial work on four key work packages.
Work Package 1: “Evidence generation throughout the entire product life cycle” led by National Institute for Clinical Excellence, AstraZeneca
Work Package 2: “Designing the MAPPs pathway” led by Top Institute Pharma, Bristol-Myers Squibb
Work Package 3: “Decision-making, sustainability and their implications” led by Centre for the Advancement of Sustainable Medical Innovation, Sanofi-Aventis Research and Development (Genzyme)
Work Package 4: “ADAPT SMART Operational Project Management” led by Top Institute Pharma
On September 4th, 2015, a coalition of 90 European healthcare stakeholders from 32 organisations met and talked about collaborative efforts to prove and develop workable MAPPs concepts. In its kick-off session, it was pointed out that one of the key bottlenecks and points of distrust, to be addressed through ADAPT SMART, is the need to involve both patients and prescribers. Yann le Cam, CEO of EURORDIS said, “We are focusing so much on putting the patients at the centre, we’re forgetting that for the products we are addressing the key relationship is between the patient and the doctor at hospital centres, where prescriptions are prescribed and the capture of real world evidence takes place. This will be key to making MAPPs a success.”
Visit the ADAPT SMART website
Friedreich ataxia is an autosomal recessive hereditary spinocerebellar disorder, characterised by progressive limb and gait ataxia due to proprioceptive loss. A cross-sectional study of the Friedreich ataxia patients in Norway identified through colleagues in neurological, paediatric and genetic departments, hospital archives searches, patients’ associations, and National Centre for Rare Disorders is published in Orphanet Journal of Rare Diseases. The authors of this study identified twenty-nine Friedreich ataxia patients in Norway, of which 23 were ethnic Norwegian, corresponding to a prevalence ratio of 1:176 000. The highest prevalence was seen in the Norwegian north. According to this study the prevalence of Friedreich ataxia in Norway is lower than in Central Europe (1:20,000 – 1:50,000), but higher than in the last Norwegian report, especially due to migratory influences. 
Lynch syndrome (LS) screening among patients with newly diagnosed colorectal cancer can decrease mortality in their affected first-degree relatives. In Germany, it is not yet in clinical practice and thus the cost-effectiveness of different testing strategies is unknown. The authors of an article published in Genetics in Medicine developed a decision-analytic model to analyse the cost-effectiveness of LS screening from the perspective of the German Statutory Health Insurance system. They studied 22 testing strategies considering family-history assessment, analysis of tumor samples and genetic sequencing were analysed. The authors observed that LS screening provides clinical benefit but at a high cost. The most cost-effective strategy involves family-history assessment with the revised Bethesda criteria, followed by IHC testing, BRAF testing, and genetic sequencing, with an ICER of €77.268 per LYG. They also found that aspirin chemoprevention provides comparatively low additional health effects and improves the cost-effectiveness of screening only slightly. 
An article published in Value in Health – Regional Issues evaluated the frequency of medical interventions in a cohort of patients with mucopolysaccharidosis (MPS) I, II, and VI, which are lysosomal storage disorders on enzyme replacement therapy (ERT) to estimate the impact of direct medical costs associated with the treatment of MPS and compare its frequency with that observed among patients not on ERT in Brazil.
Canada has been battling with Alexion over the price of Soliris - a rare disease drug that is currently the costliest in the world. It is used to treat a couple of rare blood diseases that can kill red blood cells and cause anaemia and lead to organ failure. Canada argues that the drug costs USD 669,000 in the U.S. compared to CAD 700,000 per patient per year. Canada wants Alexion to repay the price difference to the government for those provinces in Canada that reimburse this drug. All provinces in Canada do not reimburse this drug due to its prohibitive cost. In a preemptive move, Alexion has sued regulators to prevent Canada from reducing the price, stating the difference in exchange rate reflecting the difference in price. They have also argued that the Canadian agency does not have the authority to force it to lower its price on its drug. 
AFM-Telethon, and the investment fund "SPI – Agencies Industrial Projects", managed by Bpifrance, have joined forces with the aim of creating Europe's largest development centre for the production of gene and cell therapies. This project aims both to create an industrial-scale production platform what will lead the development of gene and cell therapies and help carry it to completion. This new centre aims to meet the needs of many current AFM-Telethon laboratories and those of numerous academic and biotech industry actors by offering a platform for the production of their therapies, whether they are for clinical trials or post-marketing diffusion. 
